Esophageal tolerance to high-dose stereotactic ablative radiotherapy

Diseases of the Esophagus, 04/25/2012

The authors report a dosimetric analysis of incidental dose to the esophagus from stereotactic ablative radiotherapy (SABR). High–dose hypofractionated radiotherapy led to a number of high–grade esophageal adverse events, suggesting that conservative parameters to protect the esophagus are necessary when SABR is used, especially in the setting of chemotherapy or prior radiotherapy.

Print Article Summary Cat 2 CME Report